Good news for collaboration
In order to further explore and reserve innovative technologies and enrich the company's innovative product pipeline in the field of chronic disease, Salubris announced that it entered into an agreement with YolTech Therapeutics (YolTech) to obtain exclusive rights of PCSK9 targeting base editing drug YOLT-101 in mainland China, of which including but not limited to development, registration, production and commercialization etc..
YOLT-101 is a PCSK9 targeting base editing drug independently developed by YolTech. Currently, the indications to be developed include familial hypercholesterolemia (FH). YOLT-101 is in preclinical stage, and completed its first subject administration in an investigator-initiated clinical study (IIT Study). Available preclinical data showed that YOLT-101 achieved a substantial reduction in LDL-C (low-density cholesterol) for up to two years at a time of administration in non-human primate models.
As an innovation-driven pharmaceutical company, Salubris is always patient centered and committed to developing innovative products with clinical value. Based on the concept of deep cultivation in the field of chronic diseases, Salubris focuses on cutting-edge innovative technologies, and forms an innovation platform based on small molecules, biologics, siRNA small nucleic acids and gene editing drugs, along with medical devices. Obtaining the exclusive right of YOLT-101 in mainland China is showing Salubris’ further exploration in the field of gene editing.
If the drug can be successfully developed and approved for marketing, it will significantly improve the medication compliance of patients with familial hypercholesterolemia, and provide patients with a new and more convenient treatment option, meanwhile, expanding Salubris’ innovative pipeline in the field of cardiovascular and cerebrovascular, enhancing core competitiveness, which is in line with Salubris’ development strategy.
About Salubris
Shenzhen Salubris Pharmaceuticals Co., Ltd., founded in 1998 and listed in the Shenzhen Stock Exchange in 2009 (stock code: 002294), is an innovation-driven pharmaceutical company based in China and extended worldwide in research, production and marketing. Salubris has the entire chain of innovative drug research and development capabilities, focusing on cardiovascular and cerebrovascular diseases, diabetes, cancer, osteoporosis, chronic kidney disease and other chronic diseases. With five innovative drug research and development centers worldwide, which form an innovation platform mainly for small molecules, biologics, siRNA small nucleic acid and gene editing drugs, and medical devices to develop innovative products with clinical value. Besides, Salubris continues to improve access to medicines, with products covering more than 40 countries and regions in Europe, Asia, Africa, North America and South America, benefiting countless patients.
About YolTech
YolTech Therapeutics founded in 2021 is a high-tech biomedical company focused on developing gene-editing drugs. The company has a R&D center in Shanghai headquarters and a GMP production base. Relying on multiple technological innovation platforms, the company has successfully discovered and evolved a new generation of gene editor YolCas™ and base editor YolBE®, and obtained a new type of lipid nanoparticle YOL-LNPs® with independent intellectual property rights to achieve more efficient delivery in vivo.
